hotspot -WSS

hotspot

author：explore 2025-10-02 11:10:28 - browse：835

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Despite FDA concern, risk that CAR

focus

WSS

Merck, Johnson & Johnson CEOs will testify on high drug prices

Pancreatic cancer early detection could be helped by AI

Wegovy leads to weight loss. Can it treat depression, too?

Pancreatic cancer early detection could be helped by AI

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Merck CEO won’t testify in Senate, citing no expertise in drug prices

entertainment

hotspot

knowledge

In Memoriam: Notable people who died in 2023

Reconstructing family trees of blood cells may help predict disease

The high cost of giving birth even with insurance

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Tori Bowie and the unacceptable rates of Black maternal death

Health Care Service Corp to buy Cigna Medicare Advantage plans

Activists slam private health insurers over coverage restrictions

What don’t we know about an Alzheimer’s drug side effect?

Walensky prepares to leave CDC — and Congress — behind

CDC director unscathed in first congressional testimony

hotspot

FTC sues over Novant Health acquisition of two N.C. hospitals

U.K. Biobank has 500,000 peoples' genome sequences available

Medicare drug price negotiation legal challenge met with skepticism

Medicare drug price negotiation legal challenge met with skepticism

The EPA's new lead rule: How one expert crunched the numbers

Reconstructing family trees of blood cells may help predict disease

focus

explore

explore

Wikipedia